IMA

ImageneBio Inc

5.38

Jul 17 • 03:59PM ET -0.07 (-1.28%)

5.39

Aftermarket • 05:00PM ET +0.01 (0.19%)

Healthcare Biotechnology USA Micro NASD

Peers: ANVS EXOZ FBIO ICCC MCRB OSTX PLRX PMVP XBIT FLNA

| Held by: VTI VXF IWC

Scroll to Statements

Index	-
Market Cap	63.53M
Enterprise Value	-45.53M
Income	-45.92M
Sales	0.00M
Book/sh	10.93
Cash/sh	9.93
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	15
IPO	Mar 26, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.49
P/C	0.54
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	18.39
Current Ratio	18.39
Debt/Eq	0.07
LT Debt/Eq	0.05
Option/Short	No / Yes

EPS (ttm)	-5.26
EPS next Y	-3.07
EPS next Q	-0.98
EPS this Y	57.43%
EPS next Y	25.18%
EPS next 5Y	25.70%
EPS past 3/5Y	24.93% 8.22%
Sales past 3/5Y	-62.86% -38.64%
EPS Y/Y TTM	49.30%
Sales Y/Y TTM	-100.00%
EPS Q/Q	55.80%
Sales Q/Q	-
Earnings	May 07 AMC
EPS/Sales Surpr.	-42.49% -

Insider Own	36.61%
Insider Trans	0.00%
Inst Own	29.93%
Inst Trans	0.50%
ROA	-33.70%
ROE	-37.32%
ROIC	-34.90%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-9.05%
SMA50	-6.48%
SMA200	-17.17%
Trades

Shs Outstand	10.75M
Shs Float	7.49M
Short Float	5.40%
Short Ratio	12.81
Short Interest	0.40M
52W High	18.00 -70.11%
52W Low	3.94 36.55%
Volatility	5.70% 5.24%
ATR (14)	0.32
RSI (14)	36.84
Beta	0.76
Rel Volume	0.95
Avg Volume	31.57K
Volume	30,140

Perf Week	-8.97%
Perf Month	-1.28%
Perf Quarter	-6.92%
Perf Half Y	-21.23%
Perf YTD	-22.03%
Perf Year	-64.42%
Perf 3Y	-92.27%
Perf 5Y	-96.60%
Perf 10Y	-
Recom	2.33
Target Price	13.00
Prev Close	5.45
Price	5.38
Change	-1.28%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-25-25	Resumed	Wedbush	Underperform	$2
Oct-24-25	Initiated	Leerink Partners	Outperform	$30

Jul-07-26 07:00AM	ImageneBio Appoints Matt Robbins as General Counsel (GlobeNewswire)
May-27-26 04:30PM	ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York (GlobeNewswire)
May-07-26 04:05PM	ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update (GlobeNewswire) -10.49%
Apr-13-26 07:00AM	ImageneBio Announces $30 Million Private Placement (GlobeNewswire) +23.42%
Mar-17-26 04:30PM	ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
08:00AM	Loading…
Mar-10-26 08:00AM	ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update (GlobeNewswire)
Feb-26-26 08:00AM	ImageneBio to Participate in Leerink Global Healthcare Conference (GlobeNewswire)
Feb-10-26 07:00AM	ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer (GlobeNewswire)
Nov-12-25 07:15AM	ImageneBio Reports Third Quarter 2025 Financial Results and Provides IMG-007 Program Update Following Closing of Reverse Merger, Concurrent Financing, and Strengthening of Management Team (GlobeNewswire)
Nov-06-25 08:30AM	ImageneBio to Participate in Fourth Quarter 2025 Investor Conferences (GlobeNewswire)
Aug-05-25 09:55AM	Wall Street Analysts Believe IMAGENEBIO INC (IMA) Could Rally 695.48%: Here's is How to Trade (Zacks)
Aug-01-25 04:15PM	ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-25-25 11:00AM	Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million (GlobeNewswire)

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. It focuses on the development of new medicines with differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The company was founded in February 2016, and is headquartered in San Diego, CA.

CEODr. Kristin Yarema Ph.D.

Senior VP of Finance & Operations and Principal Accounting OfficerMr. Bob Lally

Chief Strategy & Operations OfficerDr. Kurinji Pandiyan Ph.D.

Chief Technical OfficerMs. Renuka Sivendran Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SLATTERY JOSEPH P	Director	Dec 24 '25	Buy	5.99	16,000	95,840	16,000	Dec 29 04:46 PM
Bonita David P	Director	Jul 25 '25	Buy	29.90	83,611	2,499,969	287,885	Jul 30 04:51 PM
Stampacchia Otello	Director	Jul 25 '25	Buy	29.90	267,556	7,999,924	454,982	Jul 30 04:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMA

ImageneBio Inc

Upgrade your Finviz experience